Lee's Pharmaceutical Holdings Limited (0950.HK)
- Previous Close
1.150 - Open
1.150 - Bid 1.080 x --
- Ask 1.090 x --
- Day's Range
1.090 - 1.150 - 52 Week Range
1.090 - 1.750 - Volume
58,500 - Avg. Volume
50,144 - Market Cap (intraday)
641.83M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
36.33 - EPS (TTM)
0.030 - Earnings Date Mar 26, 2024
- Forward Dividend & Yield 0.02 (1.74%)
- Ex-Dividend Date May 28, 2024
- 1y Target Est
--
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
www.leespharm.com1,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 0950.HK
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0950.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0950.HK
Valuation Measures
Market Cap
677.16M
Enterprise Value
710.30M
Trailing P/E
40.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.64
Price/Book (mrq)
0.33
Enterprise Value/Revenue
0.67
Enterprise Value/EBITDA
3.71
Financial Highlights
Profitability and Income Statement
Profit Margin
1.59%
Return on Assets (ttm)
0.79%
Return on Equity (ttm)
1.05%
Revenue (ttm)
1.05B
Net Income Avi to Common (ttm)
16.7M
Diluted EPS (ttm)
0.030
Balance Sheet and Cash Flow
Total Cash (mrq)
171M
Total Debt/Equity (mrq)
10.41%
Levered Free Cash Flow (ttm)
-44.97M
Research Analysis: 0950.HK
Company Insights: 0950.HK
0950.HK does not have Company Insights